China Resources Pharmaceutical Group (HKG:3320) subsidiary China Resources Boya Bio-pharmaceutical Group (SHE:300294) expects to record net profit attributable to the shareholders between 380.00 million yuan and 480.00 million yuan in 2024, higher than 237.5 million yuan logged for the preceding year, a Wednesday Hong Kong bourse filing said.
China Resources Boya Bio-pharmaceutical Group attributed the increase in expected profit to a rise in revenue from its blood products and the impact of non-recurring gains and losses on its net profit during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.